NCT01015027已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study of the Safety and Tolerability of Intravenously Administered REGN668 in Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN668 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 85/visit 11.
研究概览
简要总结
This study will test the safety and tolerability (how the body reacts to the drug) of REGN668 and placebo (an inactive substance that contains no medicine) in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female 18 to 65 years of age.
- •Weight > 50 kg and < 120 kg.
- •For women of childbearing potential, a negative serum pregnancy test at the screening visit (visit 1) and a negative urine pregnancy test on day -
- •Willingness to refrain from the consumption of alcohol for 24 hours prior to each study visit.
- •For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner[s] become pregnant) during the full duration of the study.
- •Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
- •Able to read, understand and willing to sign the informed consent form.
排除标准
- •Onset of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to screening visit.
- •Pregnant or breast-feeding women.
- •Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the subject's participation in this study.
- •Hospitalization for any reason within 60 days of screening (visit 1).
- •Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C, and/or positive Hepatitis B surface antigen (HBsAg), positive Hepatitis C antibody (HCV).
- •Previous exposure to any therapeutic or investigational biological agent. results.
- •History of alcohol or substance abuse within previous 5 years.
结局指标
主要结局
The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN668 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 85/visit 11.
时间窗: 85 days
次要结局
- Pharmacokinetics: Serum concentrations of REGN668 over time.(85 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT01055899Regeneron Pharmaceuticals15
已完成
1 期
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic DermatitisDermatitisNCT01259323Regeneron Pharmaceuticals30
已完成
1 期
Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy VolunteersHealthyNCT01197391Regeneron Pharmaceuticals48
已完成
1 期
Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy VolunteersHealthy VolunteersNCT01074372Regeneron Pharmaceuticals32
已完成
1 期
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant AtorvastatinHypercholesterolemiaNCT01161082Regeneron Pharmaceuticals72